DEPO lacks any R&D and drug development to have any hope for future explosive income. After all, it tangle with lawsuits and high expenses. Marketing is also weak and cost s more money than income. I do not understand why such a multiple is given to this stock. It should be somewhere around $5 or max $6.
Their legal expenses (at least the last litigation against them), at any moment, are about to end. The last of the three companies that they were in litigation with has no legs to stand on and they know it!
The only legal expense will be in acquiring their next new company.